Fig. 4From: A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in ChinaKaplan-Meier analysis of DFS and OS of 81 ASCO/CAP group 2 primary breast cancer without neoadjuvant therapy. Patients of ASCO/CAP group 2 did not obtain apparent benefit from anti-HER2 therapy, either in terms of DFS (A, P = .95) or OS (B, P = .70). DFS of patients with PR positive was superior to that of patients with PR negative (C, P = .002). Patients with ratio of HER2/CEP17 ≤ 2.5 displayed a significantly better OS than those with ratio of HER2/CEP17 > 2.5 (F, P = .007)Back to article page